Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder

Key Inclusion Criteria: * Eligible subjects are those subjects who complete study BHV4157-302 or BHV4157-303 and for whom the investigator believes open-label treatment offers an acceptable risk-benefit profile. * Determined by the investigator to be medically stable at the week 10 visit of BHV4157-302 or BHV4157-303, as assessed by medical history, physical examination, laboratory test results, and electrocardiogram testing. * It is required that all women of child-bearing potential (WOCBP) who are sexually active agree to use two methods of contraception for the duration of the study Key Exclusion Criteria: * Subjects who did not successfully complete 10 weeks of treatment in the BHV4157-302 or BHV4157-303 study. * Acute suicidality or suicide attempt or self injurious behavior in the last 12 months. * Patients who may have received a non-biological investigational agent in any clinical trial within 30 days or a biological agent within 90 days prior to entry, other than what was received in BHV4157-302 or BHV4157-303;

Reproduced word-for-word from the public registry record — the study team can answer questions about it.